Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord mesenchymal stem cells (Aspire Biotech)
- Development stage
- Unknown
- Lead developer
- Aspire Health Science
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular, Intrathecal, Local Injection, Topical, Intramyocardial, Intracoronary, Intrahepatic
01
Overview
Human umbilical cord mesenchymal stem cells (HUCMSCs) are multipotent stromal cells derived from the Wharton's jelly of the human umbilical cord. They possess strong immunomodulatory and anti-inflammatory properties, including inhibition of natural killer cell, T-cell, and B-cell proliferation, as well as modulation of monocytes and dendritic cell maturation. HUCMSCs secrete factors such as TSG-6 that contribute to tissue repair by reducing inflammation and promoting regeneration in various disease models. These cells are being investigated for a wide range of indications including wound healing, spinal cord injury, osteoarthritis, liver disease (such as decompensated cirrhosis), kidney disease, cardiovascular conditions, neurological disorders, and immune system diseases. They are typically considered investigational products with ongoing clinical trials assessing their safety and efficacy[1][2][4][5][6].
- Other names
- human umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on Human umbilical cord mesenchymal stem cells (Aspire Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human umbilical cord mesenchymal stem cells (Aspire Biotech).